In a research note all the way back in April 2020, I predicted that shares of Atomera Inc. (ATOM) would top $25 on the first joint development agreement (JDA).
Well, that came to pass this morning, prompting many people to ask: “What do you expect to propel shares higher from here?”
You mean the run up from $3.27 since we first started buying isn’t enough?! Apparently not.
Before I share the next potential catalysts, a quick head’s up…
Make sure you keep an eye on your inbox tomorrow or Monday.
I’m finalizing my research on a new recommendation in the biotech sector ahead of next week’s JP Morgan Healthcare Conference.
It’s similar to Lantern Pharma Inc. (LTRN) in that it’s still completely under-the-radar and trading below its IPO price with multiple short-term catalysts. More details to follow.
Right now, it’s time to get back to what matters regarding Atomera…
Want to keep reading? No problem! All you have to do is sign up for FREE here as a registered user.
By doing so, you agree to receive periodic research updates from DTR and only DTR.
We will never rent, sell or share your info.